Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics
Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics
复制标题
通过氨基甲酸酯前药方法提高他喷他多的口服生物利用度:合成、生物活化和药代动力学
DOI:
10.1007/s13346-018-0524-6
复制
发表时间:
2018-05
影响因子:
5.4
通讯作者:
Tianhong Zhang
中科院分区:
文献类型:
--
作者:
Yingchao Li;Yongjun Wang;Ran Zhang;Cuiru Liu;Yue Wei;Jin Sun;Zhonggui He;Youjun Xu;Tianhong Zhang
Tapentadol suffers from rapid clearance due to extensive metabolism in vivo, which results in low oral bioavailability. In the present study, three novel prodrugs of tapentadol (WWJ01, WWJ02, and WWJ03) were synthesized to improve its metabolic stability and thereby improve its oral bioavailability. They all exhibited good stability in phosphate buffers, simulated gastrointestinal fluids, rat plasma, and intestinal and liver homogenates. Disappointingly, the N,N-diethylcarbamate prodrug of tapentadol (WWJ02) and the N,N-diisopropylcarbamate prodrug of tapentadol (WWJ03) were metabolized into inactive metabolites when incubated with liver microsomes. In contrast, the N,N-dimethylcarbamate prodrug of tapentadol (WWJ01) could be transformed into useful intermediates (M1, M2, and M3), followed by the further release of the active structure (tapentadol) with the addition of plasma. Additionally, the possible biotransformation pathway of WWJ01 was preliminarily studied with a qualitative approach by determining the molecular weight and fragment ions of its metabolic intermediates. Finally, pharmacokinetic studies were carried out to evaluate the oral absorption of WWJ01. WWJ01 showed distinct advantages in oral absorption efficiency, with a 2.3-fold higher bioavailability than tapentadol. These results suggest that the rational design of a carbamate prodrug of tapentadol is an efficient strategy to improve its metabolic stability and oral bioavailability.
登录
查看更多内容
影响因子:
3.2
作者:
C. Hartrick;Jose Rafael Rodríguez Hernandez
通讯作者:
C. Hartrick;Jose Rafael Rodríguez Hernandez
DOI:
--
发表时间:
1989-05
期刊:
Drug metabolism and disposition: the biological fate of chemicals
影响因子:
--
作者:
C. Lindberg;C. Roos;A. Tunek;L. Svensson
通讯作者:
C. Lindberg;C. Roos;A. Tunek;L. Svensson
DOI:
10.1358/mf.2010.32.1.1434165
发表时间:
2010
影响因子:
--
作者:
R. Terlinden;B. Y. Kögel;W. Englberger;T. Tzschentke
通讯作者:
R. Terlinden;B. Y. Kögel;W. Englberger;T. Tzschentke
影响因子:
3
作者:
Zhipei Sang;X. Qiang;Yan Li;Bei Wu;Hui Zhang;Mingsheng Zhao;Yong Deng
通讯作者:
Zhipei Sang;X. Qiang;Yan Li;Bei Wu;Hui Zhang;Mingsheng Zhao;Yong Deng
DOI:
--
发表时间:
2006-09
期刊:
Pharmacological reports : PR
影响因子:
--
作者:
A. Stańczak;A. Ferra
通讯作者:
A. Stańczak;A. Ferra